Bronchiectasis Financial Crisis — When Cover Is Failing

Emergency / crisis support: /emergency

If inhaled antibiotics have been declined, a severe exacerbation is generating unexpected costs, your physiotherapy access has been cut, or CDL medications are being incorrectly charged to your savings account — this guide covers the steps.

Severe Exacerbation Requiring Hospitalisation

If you are acutely unwell with high fever, significant worsening of breathlessness, large-volume haemoptysis, or altered consciousness:

• Seek emergency care immediately. Severe bronchiectasis exacerbations requiring IV antibiotics are PMB-covered.
• If pre-authorisation is possible, contact the scheme's emergency line before or during admission.
• If the admission is an emergency and pre-authorisation is not possible, retrospective authorisation applies under PMB rules — you cannot be refused admission for a PMB emergency.
• Request a case manager through your scheme's hospitalisation line once admitted.
• Large-volume haemoptysis (coughing up significant quantities of blood) is a medical emergency — call an ambulance immediately.

Common Bronchiectasis Financial Crises

1. Inhaled tobramycin or colistin declined for confirmed Pseudomonas bronchiectasis
2. CDL medications (azithromycin, hypertonic saline) being charged to MSA
3. Physiotherapy benefit exhausted before year-end
4. IV antibiotic admission generating unexpected out-of-pocket costs
5. Repeated authorisation demands for exacerbation antibiotic courses

If Inhaled Antibiotics Were Declined

Inhaled antibiotic therapy for confirmed Pseudomonas aeruginosa bronchiectasis is supported by international guidelines (ERS Bronchiectasis Guidelines 2017). A decline is worth appealing.

Step 1: Request the written decline letter with clinical reasoning.

Step 2: Your pulmonologist submits an enhanced exceptional-needs motivation: - Positive sputum culture results with dates (two positive cultures >3 months apart) - Antibiotic sensitivities confirming tobramycin or colistin sensitivity - Exacerbation frequency (hospitalisations and outpatient courses per year) - FEV1 trend over 12–24 months - ERS guideline reference for inhaled antibiotics in Pseudomonas-positive bronchiectasis - Economic argument: cost of one prevented hospitalisation vs annual inhaled antibiotic cost

Step 3: Request a peer-to-peer clinical review between your pulmonologist and the scheme's medical advisor.

Step 4: If still declined, formal internal appeal with the enhanced motivation. If that fails, CMS escalation.

Preventing one IV antibiotic admission (R50,000–R120,000) can justify an entire year of inhaled antibiotic therapy. This is a fundable, evidence-backed treatment — do not accept a first decline as final.

If CDL Medications Are Being Charged to MSA

Re-confirm CDL registration status with the scheme. Occasionally, CDL registrations are not correctly linked to dispensing records at the pharmacy. Steps:

1. Request written CDL registration confirmation from the scheme (showing active status for J47 Bronchiectasis)
2. Ask the scheme to issue a corrected authority code for the affected medications
3. Request reprocessing of prior claims that were incorrectly processed against MSA

Azithromycin prescribed as long-term prophylaxis for CDL-registered bronchiectasis is CDL-eligible treatment — not a standard antibiotic course. The prescription indication drives the benefit categorisation.

If Physiotherapy Benefit Is Exhausted

When the standard physiotherapy benefit is exhausted mid-year:

1. Ask your pulmonologist to submit a CDL physiotherapy motivation to the scheme — a clinical letter stating that ongoing airway clearance physiotherapy is a medical necessity for CDL-registered bronchiectasis and requesting authorisation of additional sessions beyond the standard benefit limit. This succeeds for a meaningful proportion of patients.

2. Ask whether a pulmonary rehabilitation programme provides an alternative physiotherapy access pathway — rehabilitation programmes are sometimes budgeted separately from the outpatient physiotherapy benefit.

3. If additional sessions cannot be authorised: invest in a home-use airway clearance device (oscillating PEP device; R2,000–R5,000 once-off). A respiratory physiotherapist can teach the technique in 2–4 sessions — after which you maintain the daily routine independently without ongoing benefit consumption.

Repeated Exacerbation Authorisation Burden

If the scheme requires individual authorisation for every exacerbation antibiotic course, ask your pulmonologist to establish an annual standing authorisation protocol for established bronchiectasis — a pre-approved antibiotic algorithm (e.g., amoxicillin-clavulanate first-line for non-Pseudomonas; ciprofloxacin for Pseudomonas) valid for 12 months without requiring repeated individual authorisations. Many schemes will issue this for well-documented chronic conditions. This is particularly important for managing exacerbations promptly — delays in authorisation mean delays in antibiotic treatment.

Triage Table

Escalation Contacts

Council for Medical Schemes (CMS): 0861 123 267 | www.medicalschemes.org.za Lung Association of South Africa: www.lungsa.org.za AURA Emergency: /emergency

Talk to Eldon

Get urgent help with your cover situation →

This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).